Drug Trial News

RSS

New typhoid conjugate vaccine shows safety and strong immune response in Africa

PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.®

12 Nov 2025

Evolocumab shows clear benefit in preventing first-time heart attacks and strokes

Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular events in adults with atherosclerosis or high-risk diabetes who had never had a heart attack or stroke. The 4.6-year study confirmed durable safety and benefit, supporting earlier, more intensive LDL cholesterol control.

11 Nov 2025

Metformin shows promise in treating AFib recurrence after ablation

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

New data supports earlier use of evolocumab in high-risk diabetes

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes , according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Comparative study finds higher rates of adverse events with ticagrelor

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association's Scientific Sessions 2025 in New Orleans on November 10.

10 Nov 2025

Prasugrel shows advantage over ticagrelor in diabetic patients after stent placement

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit at preventing stent clotting, heart attacks and bleeding complications, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Single daily polypill improves heart function and quality of life in heart failure patients

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, better quality of life, fewer hospitalizations and greater medication adherence than those taking the medications individually, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.

10 Nov 2025

One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Daily oral medication matches injectable therapies in reducing bad cholesterol

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density lipoprotein (LDL or "bad" cholesterol), according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors with preserved cardiac function enrolled in five global clinical trials.

10 Nov 2025

Tailored vitamin D3 supplementation lowers risk of heart attack recurrence

A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart attack, a new study from heart researchers at Intermountain Health in Salt Lake City finds.

10 Nov 2025

Triglyceride-lowering drug can also decrease the risk of acute pancreatitis

Researchers from Mass General Brigham have found that olezarsen-a drug designed to lower triglyceride levels-can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels.

10 Nov 2025

Experimental intranasal vaccine triggers broad immune response against multiple strains of H5N1

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 "bird flu".

6 Nov 2025

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton's tyrosine kinase inhibitors (BTKi).

6 Nov 2025

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.

5 Nov 2025

Sertraline contributes to a modest improvement in core depression and anxiety symptoms

One of the most common antidepressants, sertraline, contributes to a modest improvement in core depression and anxiety symptoms, including low mood, within two weeks, finds a new analysis of a major clinical trial led by UCL researchers.

30 Oct 2025

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

New drug can have a promising effect in cancer patients with active brain metastases

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumor types.

28 Oct 2025

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.

26 Oct 2025

1
2
3
4
...
1159
Next

Drug Trial News

New typhoid conjugate vaccine shows safety and strong immune response in Africa

Evolocumab shows clear benefit in preventing first-time heart attacks and strokes

Metformin shows promise in treating AFib recurrence after ablation

New data supports earlier use of evolocumab in high-risk diabetes

Comparative study finds higher rates of adverse events with ticagrelor

Prasugrel shows advantage over ticagrelor in diabetic patients after stent placement

Single daily polypill improves heart function and quality of life in heart failure patients

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial

Daily oral medication matches injectable therapies in reducing bad cholesterol

Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function

Tailored vitamin D3 supplementation lowers risk of heart attack recurrence

Triglyceride-lowering drug can also decrease the risk of acute pancreatitis

Experimental intranasal vaccine triggers broad immune response against multiple strains of H5N1

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

Sertraline contributes to a modest improvement in core depression and anxiety symptoms

WHO reviews highlight limited long-term data on GLP-1 drug safety

New drug can have a promising effect in cancer patients with active brain metastases

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News